Honeywell and Wolters Kluwer team up to help employees safely return to the workplace
Honeywell and Wolters Kluwer today announced a collaboration to integrate Honeywell’s Industrial Internet of Things (IIoT) connected devices and safety software with the risk and environmental, health and safety (EHS) software from Enablon, a Wolters Kluwer business. The collaboration is designed to enable enterprises in asset-intensive industries to improve their risk, safety and operational excellence programs.
The collaboration enables customers to monitor their EHS performance, receive early warnings about issues from their Honeywell equipment and take proactive steps to help prevent incidents and improve safety compliance.
- Before visiting the facility, Honeywell’s Digitized Workforce Management software provides an electronic questionnaire which, when complete, provides an access code and time of arrival to reduce the need for transfer of paper documents and improve social distancing.
- At the entryway, the connected safety software solutions allow Honeywell’s artificial intelligence-driven elevated body temperature monitoring solutions to conduct non-invasive, preliminary screenings of personnel entering a facility.
- The system also detects if individuals are wearing the required personal protective equipment needed for entering the building and if they are doing so properly, in compliance with safety regulations.
- These data points and other manual data points are then reported to the Enablon EHS software.
- Through a dashboard view, management can monitor workers to ensure that they remain compliant with rapidly changing health and safety regulations. The EHS solution also allows frontline operations employees to carry out measurements, checks and recordings directly in the field, without the need to walk back and forth to a control room.
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more